Viridian Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock and Series B preferred stock. Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock and Series B preferred stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes. Jefferies and Leerink Partners are acting as joint lead book-running managers for the proposed offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRDN:
- Spyre Therapeutics price target raised to $36 from $27 at Stifel
- Apogee Therapeutics price target raised to $46 from $34 at Stifel
- Short Report: Bears boost exposure to Rocket Companies despite dovish Fed tilt
- Viridian Therapeutics price target raised to $36 from $35 at Oppenheimer
- 3 Best Stocks to Buy Now, 12/19/2023, According to Top Analysts